CV

CapsoVision, Inc.

CapsoVision, Inc. (CV) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Profitability (C). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B-
Factor Score 2.9 / 5.0
Growth
C+
Factor Score 2.6 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
B-
Factor Score 3.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA -10.5
Rev Growth YoY 9.9%
Gross Margin 50.9%
Price Return 3M -7.1%
Price Return 12M 34.7%
Catalyst Signal 0.00
Market Cap $338.9M
TTM Revenue $13.9M
Price / Sales 24.4
ROE -335.1%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B- (2.9) C+ (2.6) C (2.4) B- (3.0) C+ (2.6) C+ (2.7)
2026-11-04 B- (2.9) C+ (2.6) C+ (2.5) B- (3.0) C+ (2.7) C+ (2.7)
2026-10-28 B- (2.9) C+ (2.6) C+ (2.5) B- (3.0) C+ (2.7) C+ (2.7)
2026-10-21 B- (2.9) C+ (2.6) C (2.5) C+ (2.7) C+ (2.6) C+ (2.7)
2026-10-14 B- (2.9) C+ (2.6) C (2.5) B- (3.0) C+ (2.6) C+ (2.7)
Page 1 of 4